Diagnostic strategy in heparin induced thrombocytopenia

Year 2009, Volume: 14 Issue: 2, 78 - 83, 14.01.2013

Meganathan Kannan Sarfraz Ahmad Jawed Fareed Renu Saxena

Abstract

Abstract. Heparin-induced thrombocytopenia occurs due to the formation of antibodies against the complex formed between heparin and platelet factor 4 (H-PF4) leading to platelet/endothelial cell activation followed by thrombocytopenia.  Diagnosis of H-PF4 antibodies are mainly based on two different assays; functional and immunologic assays.  While the functional assays are based on the platelet activation, the immunogical assays are based on the binding of IgG antibodies to H-PF4 complexes.  Even though ¹⁴C-Serotonin Release Assay is high in sensitivity, the most commonly used functional assays are Platelet aggregation test  and Heparin-ınduced platelet aggregation  The immunologic assays include solid-phase detection, fluid-phase detection, enzyme-linked lmmunosorbent assay, particle gel immunoassay; the commonly used is enzyme-linked ımmunosorbent assay   occurrence of HIT may vary not only based on the patients’ group but also based on the type of diagnostic technique used.  The methodological variations observed in our experience are discussed in this review.  In the current review we discuss the diagnostic approach, importance in the diagnosis of FcgRIIa receptor polymorphism, controversies in diagnosis of HIT and preventive measures.

Key words: Trombocytopenia, diagnostic approach, clinical and laboratory diagnosis

Keywords

Trombocytopenia, diagnostic approach, clinical and laboratory diagnosis

References

• Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2007; 21: 589-607.
• Gitau MM, Arora N. Heparin-induced thrombocytopenia. Mo Med 2009; 106: 50-54.
• Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood ; 112: 2607-2616.
• Unkle DW. Heparin-induced thrombocytopenia. Orthop Nurs 2007; 26: 383-5; quiz 386-387.
• Amiral J, Marfaing-Koka A, Poncz M, Meyer D. The biological basis of heparin-induced thrombocytopenia. Platelets 1998; 9: 77-91.
• Swanson JM. Heparin-induced thrombocytopenia: a general review. J Infus Nurs 2007; 30: 232-240.
• Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost 2006; 32: 803-809.
• Warkentin TE. Clinical picture of HIT. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenis. 3rd Edition. New York, NY: Marcel Dekker 2004; 53-106.
• Kannan M, Saxena R, Adiguzel C, Fareed J. An update on the prevalence and characterization of H- PF4 antibodies in Asian-Indian patients. Semin Thromb Hemost 2009; 35: 337-343.
• Ahmad S, Untch B, Haas S, et al. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: Implications in the HIT pathogenesis. Mol Cell Biochem 2004; 258: 163-170.
• Fabris F, Ahmad S, Cella G, Jeske WP, Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia: Clinical and diagnostic implications – a review. Arch Pathol Lab Med ; 124: 1657-1666.
• Castelli R, Cassinerio E, Cappellini MD, Porro F, Graziadei G, Fabris F. Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects. Cardiovasc Hematol Disord Drug Targets 2007; 7: 153-162.
• Kannan M, Ahmed R, Kale S, Ahmad S, Fareed J, Saxena R. Laboratory diagnosis of heparin-induced thrombocytopenia in Asian Indians as investigated with functional and immunologic methods. Clin Appl Thromb Hemost 2004; 10: 51-54.
• Elalamy I, Lecrubier C, Horellou MH, Conard J, Samama MM. Heparin-induced thrombocytopenia: Laboratory diagnosis and management. Ann Med ; 32: 60-67. Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin- induced thrombocytopenia: an update. Semin Thromb Hemost 2008; 34: 86-96
• Kannan M, Ahmad S, Ahmad F, et al. Functional characterization of antibodies against heparin-PF4 complex in heparin-induced thrombocytopenia patients in Asian-Indians: inflammatory markers Blood Coagul Fibrinolysis ; 16: 487-490. Walenga JM, Jeske WP, Wood JJ, Ahmad S, Lewis BE, Bakhos M. Laboratory tests for heparin- induced thrombocytopenia: A multicenter study. Semin Hematol 1999; 36: 22-28.
• Lee DH, Warkentin TE, Denomme GA, Hayward CP, Kelton JG. A diagnostic test for heparin- induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol ; 95: 724-731. Risch L, Bertschmann W, Heijnen IA, Huber AR. A differentiated approach to assess the diagnostic usefulness of a rapid particle gel immunoassay for the detection of antibodies against heparin-platelet factor 4 in cardiac surgery patients. Blood Coagul Fibrinolysis 2003; 14: 99-106.
• Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest ; 126: 311S-337S. Brandt JT, Isenhart CE, Osborne JM, et al. Anderson, 1995. On the role of platelet Fc gamma
• RIIa phenotype in heparin-induced thrombocytopenia. Thromb. Haemost 1995; 74: 1572.
• Lehrnbecher TL, Foster CB, Zhu S, et al. Blauvelt and S.J. Chanock, Variant genotypes of FcgammaRIIIA influence the development of Kaposi's sarcoma in HIV-infected men. Blood ; 95: 2386-2390.
• Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost. ; 34: 39-57. Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost ; 34: 58-73.
• Krauel K, Fürll B, Warkentin TE, et al. Heparin- induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 2008; 6: 2160-2167.
• Selleng K, Selleng S, Greinacher A. Heparin- induced thrombocytopenia in intensive care patients. Semin Thromb Hemost 2008; 34: 425
• DiGiovanni CW. Current concepts review: heparin- induced thrombocytopenia. Foot Ankle Int. 2008; : 1158-1167.
• Selleng K, Selleng S, Greinacher A. Heparin- induced thrombocytopenia in intensive care patients. Semin Thromb Hemost 2008; 34: 425
• Hassell K. Heparin-induced thrombocytopenia: diagnosis and management. Thromb Res 2008; 123 : S16-21. Relevance to
• Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood. ; 112: 2607-2616.
• Alberio L. Heparin-induced thrombocytopenia: some working hypotheses on pathogenesis, diagnostic strategies and treatment. Curr Opin Hematol 2008; 15: 456-464.
• Linkins LA, Warkentin TE. The approach to heparin-induced thrombocytopenia. Semin Respir Crit Care Med 2008; 29: 66-74.
• Kannan M, Ahmad F, Ahmad S, et al. Heparin-PF4 Antibodies in Heparin Induced Thrombocytopenia: Its Relationship with FcgRIIa Polymorphism. Am J Immunol. 2005; 1: 55-59.
• Warkentin TE. Clinical picture of HIT. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenis. 3rd Edition. New York, NY: Marcel Dekker 2004; 53-106.
• Kannan M, Ahmad S, Ahmad F, et al.Functional characterization of antibodies against heparin-PF4 complex in heparin-induced thrombocytopenia patients in Asian-Indians: inflammatory markers Blood Coagul Fibrinolysis ; 16: 487-490. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood ; 67: 27-30. Relevance to Walenga JM, Jeske WP, Wood JJ, et al. Laboratory tests for heparin-induced thrombocytopenia: A multicenter study. Semin Hematol 1999; 36: 22-28.
• Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; : 35S-45S.
• Zwicker JI, Uhl L, Huang WY, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2: 2133-2137.
• Chilver-Stainer L, Lammle B, Alberio L. Titre of anti-heparin/PF4 antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thromb Haemost 2004; 91: 276-282.
• Brieger DB, Mak KH, Kottke-Marchant K. Heparin-induced thrombocytopenia. J. Am. Coll. Cardiol 1998; 31: 1449-1459.
• Carlsson LE, Santoso S, Baurichter G, et al. Greinacher, Heparin-induced thrombocytopenia: new insights into the impact of the FcgammaRIIa- R-H131 polymorphism. Blood 1998; 92: 1526
• Warkentin TE, Kelton JG. A 14 year study of heparin induced thrombocytopenia. Am. J. Med ; 101: 502-507. Nand S, Wong W, Yuen B, et al. Heparin Induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors and clinical outcomes in consecutive patients treated as a single institution. Am J Hematol 1997; 56: 12-16.